ReviewViruses2025
Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease.
Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association Between the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index and Tissue-Confirmed Cytomegalovirus Colitis in Patients with Active Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2026Article
- First Reported Case of Upadacitinib-Associated Cytomegalovirus Viremia and Suspected Pneumonitis in Ulcerative Colitis.ACG case reports journal · 2026Article
- Detection of Cytomegalovirus in Patients Attending a Tertiary Care Center: A Retrospective Analysis.Cureus · 2026Article
- Article
- Overlapping Cytomegalovirus Infection and Inflammatory Pouchitis After Liver Transplantation: When Antivirals Alone Are Insufficient.Gastro hep advances · 2026Article
- Cytomegalovirus Infection Is Associated with Increased Disease Activity and Worse Long-Term Course in Ulcerative Colitis.International journal of medical sciences · 2026Article
- Cytomegalovirus Gastrointestinal Disease Masquerading as Inflammatory Bowel Disease in a Patient with Occult HIV Infection Receiving Biologics: A Case Report.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) colitis, a complication in patients with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), is a significant diagnostic and therapeutic challenge due to its overlap with IBD flares. CMV reactivation in IBD is driven by chronic inflammation, compromised immune function, and use of immunosuppressive agents like corticosteroids. Risk factors include older age, pancolitis, and severe disease. Diagnosis hinges on endoscopy and histology, with tissue biopsy and immunohistochemistry as the gold standard. Quantitative tissue PCR may aid in differentiating latent from active infection. CMV colitis exacerbates IBD symptoms, prolongs hospitalization, and increases colectomy rates. Antiviral therapy, primarily ganciclovir, improves outcomes in patients with corticosteroid-refractory UC. Treatment focuses on tapering corticosteroids, optimizing biologic therapies such as infliximab, and a careful application of antivirals tailored to disease severity and viral load. Further research is needed to refine diagnostic thresholds and treatment strategies to mitigate CMV's impact on IBD prognosis. Early identification and individualized management are critical to improving clinical outcomes and reducing morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.